The identification of partial deficiency of HNF4α and GR as potential key drivers of NAFLD and hyperlipidemia may help develop novel pharmaceutical and dietary interventions for HFHS-induced NAFLD and CAD. Here, HNF4A is linked to metabolic dysfunction-associated steatotic liver disease.